Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
Authors
Stephen Chan
Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
Stephen Chan , Valeriy Vladimirovich Breder , Yu Yun Shao , David Tai , Imam Waked , Sandip Ganguly , Ashwaq Alolayan , Ahmed Aboutaleb , Heba Farag , Min-Hee Ryu
Organizations
Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation, National Taiwan University Hospital, Taipei City, Taiwan, National Cancer Center, Singapore, Singapore, Hepatology Department National Liver Institute, Menoufiya University, Shebeen El Kom, Egypt, Tata Memorial Centre, Kolkata, India, Department of Oncology, King Abdulaziz Medical City-Central Region, Riyadh, Saudi Arabia, AstraZeneca, Cairo, Egypt, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Research Funding
AstraZeneca International
Background: Recent advances in systemic therapies have revolutionized the management of HCC. However, there is limited real-world data on treatment patterns and survival outcomes in pts with uHCC. OREIOS (NCT05239507) study determined the clinical characteristics, management patterns and survival outcomes in pts with uHCC from 12 countries across Asia, Latin America, and Middle East and Africa. Methods: This non-interventional, retrospective study included pts with Barcelona Clinic Liver Cancer (BCLC) stage B or C unresectable or advanced/metastatic HCC at index date (date of diagnosis), diagnosed between January 2017 and December 2019. We present the clinicodemographic characteristics, treatment patterns, median overall survival (mOS), landmark survival (12 and 24 months), and median progression-free survival (mPFS). Results: A total of 1115 pts (median [range] age: 63 [18.0-97.0] yrs) were assessed; 83.2% (928/1115) were males, 49.1% (422/859) were current or ex-smokers, 21.4% (122/571) consumed alcohol. Most common etiologies were hepatitis B (48.9% [529/1082]), hepatitis C (23.1% [250/1082]) and alcoholic liver disease (6.6% [72/1082]). At index date, 22.3% (249/1115) and 77.7% (866/1115) presented with BCLC stage B and C, respectively with main portal vein invasion in 23.5% (262/1114), >50% liver involvement in 23.1% (250/1081) and extrahepatic metastases in 48.5% (541/1115). After index date, treatment modalities included systemic therapy (88.2% [992/1112] (including sorafenib [77.5%], nivolumab [21.3%], lenvatinib [19.8%], regorafenib [15.6%]), transarterial chemoembolization (TACE) (20.8% [232/1115]), and surgery (2.6% [29/1115]). The mPFS was 6.6 (95% CI 6.0, 7.2) months and mOS was 13.1 (95% CI 11.6, 14.2) months. Conclusions: Our study provides real-world data on treatment patterns and reports poor prognosis with pts reaching a mOS of ∼13 months. With novel agents and combination therapies being approved for uHCC, integrating them in routine care is important to improve survival. Alongside, further real-world studies are warranted for evaluating the change in treatment patterns and prognosis. Clinical trial information: NCT05239507.
| Variables | mPFS (months) (95% CI) | mOS (months) (95% CI) | OS rates (%) (95% CI) | |
|---|---|---|---|---|
| 12-month | 24-month | |||
| Overall (N=1115) | 6.2 (5.5, 6.7) | 13.1 (11.6, 14.2) | 52.2 (49.1, 55.2) | 30.7 (27.9, 33.5) |
| BCLC B (N=249) | 8.9 (6.9, 11.0) | 18.6 (16.3, 22.2) | 66.2 (59.8, 72.0) | 39.1 (32.7, 45.5) |
| BCLC C (N=866) | 5.5 (4.8, 6.1) | 11.1 (9.8, 12.7) | 48.1 (44.7, 51.5) | 28.2 (25.1, 31.4) |
| TKIs (N=889) | 5.4 (4.8, 6.0) | 13.2 (12.0, 14.5) | 53.3 (49.9, 56.6) | 30.9 (27.8, 34.1) |
| Immune Checkpoint Inhibitors (N=325) | 6.1 (4.0, 8.1) | 19.4 (15.8, 22.2) | 64.5 (59.0, 69.7) | 41.1 (35.7, 46.7) |
| VEGF-mAb/VEGFR2 mAb (N=22) | - | 27.0 (21.2, 33.8) | 81.5 (61.9, 93.7) | 59.2 (38.8, 77.6) |
| Combination therapy (N=21) | 8.5 (3.4, NA) | 20.6 (10.5, 26.1) | 66.7 (43.0, 85.4) | 38.1 (18.1, 61.6) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT05239507
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 449)
DOI
10.1200/JCO.2024.42.3_suppl.449
Abstract #
449
Poster Bd #
A14
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Gastrointestinal Cancers Symposium
Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study.
First Author: Masafumi Ikeda
Abstract
2022 ASCO Annual Meeting
Combination of transarterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) compared to TACE alone as bridging therapy transplant recipients with hepatocellular carcinoma: An update.
First Author: Abdullah Esmail
Abstract
2023 ASCO Annual Meeting
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.
First Author: Lorenza Rimassa
Abstract
2023 ASCO Annual Meeting
Clinical characteristics and initial treatment patterns of patients with HCC in Korea: A multi-center real-world database analysis from the LINK research network.
First Author: Kyu-Pyo Kim